Major Depressive Disorder KOL Interview – UK
Major Depressive Disorder KOL Interview – UK
$599.00
A UK key opinion leader (KOL) provides insight into the critical unmet needs in the depression market, along with future trends. Key late-phase pipeline drugs for major depressive disorder and post-partum depression are covered, with particular focus on Johnson & Johnson’s esketamine.
Publisher: Biomedtracker
- Highlights
- Description
Highlights
- “The biggest problem is that the drugs do not work often enough, and well enough, so you get lots of people who just do not respond, and we obviously do not know who to give what drug to, so we have to cycle around drugs until we get people better, and there are problems with side effects, and if we could have particularly – well, all of them, the weight gain, sexual dysfunction are big problems, and if we could avoid those that would be great, and I guess if we had a drug that could rapidly help suicidality that was available, that would be cool.”
Drug Coverage
- Abilify
- ALKS 5461
- BuSpar
- Cymbalta
- Esketamine
- Fetzima
- ketamine
- Lexapro
- Pristiq
- Prozac
- Rapastinel
- Rexulti
- SAGE-217
- Seroquel
- Travivo
- Trintellix
- Viibryd
- Vraylar
- Zulresso
Overview
A UK key opinion leader (KOL) provides insight into the critical unmet needs in the depression market, along with future trends. Key late-phase pipeline drugs for major depressive disorder and post-partum depression are covered, with particular focus on Johnson & Johnson’s esketamine.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
The Case For CAR-T Grows As Responses Hold Up Longer Term 
Sign up to the